Results 31 to 40 of about 6,382,401 (301)

Renal Cell Carcinoma [PDF]

open access: yesJournal of Urology, 1982
The clinical presentation of renal cell carcinoma is often diverse and outcome is notoriously difficult to predict. The only therapy for renal cell carcinoma with curative potential is radical surgery for patients presenting with locoregional disease.
openaire   +4 more sources

Quantitative proteomics in resected renal cancer tissue for biomarker discovery and profiling [PDF]

open access: yes, 2014
BACKGROUND: Proteomics-based approaches for biomarker discovery are promising strategies used in cancer research. We present state-of-art label-free quantitative proteomics method to assess proteome of renal cell carcinoma (RCC) compared with noncancer ...
J T-J Huang   +26 more
core   +1 more source

Atraumatic Ruptured Giant Renal Tumor

open access: yesThe Annals of African Surgery, 2020
Massive hemoperitoneum due to spontaneous rupture of renal cell carcinoma is a rare presentation during emergency laparotomy. A 60-year-old female patient presented with severe abdominal pain, nausea, vomiting and abdominal distension.
Gezahen Negusse Ayane, Khutsafalo Kadimo
doaj  

The long noncoding RNA urothelial carcinoma-associated 1 overexpression as a poor prognostic biomarker in clear cell renal cell carcinoma

open access: yesTumor Biology, 2017
Long noncoding RNA urothelial carcinoma-associated 1 has previously played important roles in cancer. However, its role is still unknown in clear cell renal cell carcinoma.
Yang Wang   +4 more
doaj   +1 more source

Effect of Long-chain Non-coding RNA FILNC1 Targeting c-Myc Expression on Biological Behavior of Renal Cell Carcinoma

open access: yesZhongliu Fangzhi Yanjiu, 2018
Objective To investigate the effect of long-chain non-coding RNA FILNC1 targeting c-Myc expression on the biological behavior of renal cell carcinoma. Methods qPCR was used to detect the expression of FILNC1 in renal cell carcinoma tissues and different ...
ZHANG Xiaofang, ZHAO Ying, LI Qi
doaj   +1 more source

ПРАКТИЧЕСКИЕ РЕКОМЕНДАЦИИ ПО ПРЕДОТВРАЩЕНИЮ И КОРРЕКЦИИ ПОБОЧНЫХ ЭФФЕКТОВ СУНИТИНИБА [PDF]

open access: yes, 2010
At present Sunitinib is the drug of choice in the treatment of metastatic renal cell carcinoma. In some cases complications due to the use of the drug make it to be unreasonably discontinued, which potentially affects the results of therapy.
S. L. Gutorov   +3 more
core   +1 more source

Association of dyslipidemia with renal cell carcinoma: a 1∶2 matched case-control study. [PDF]

open access: yesPLoS ONE, 2013
Abnormal serum lipid profiles are associated with the risk of some cancers, but the direction and magnitude of the association with renal cell carcinoma is unclear.
Chunfang Zhang   +8 more
doaj   +1 more source

Enhancer of zeste homolog 2 (EZH2) expression is an independent prognostic factor in renal cell carcinoma [PDF]

open access: yes, 2010
Background: The enhancer of zeste homolog 2 (EZH2) gene exerts oncogene-like activities and its (over)expression has been linked to several human malignancies. Here, we studied a possible association between EZH2 expression and prognosis in patients with
Johannes Hüsing   +29 more
core   +2 more sources

Transient down-regulation of beta1 integrin subtypes on kidney carcinoma cells is induced by mechanical contact with endothelial cell membranes [PDF]

open access: yes, 2007
Adhesion molecules of the integrin beta1 family are thought to be involved in the malignant progression renal cell carcinoma (RCC). Still, it is not clear how they contribute to this process.
Jones, Jon   +15 more
core   +1 more source

Redefining Renal Cell Carcinoma: A Molecular Perspective on Classification and Clinical Implications [PDF]

open access: yes, 2023
Renal cell carcinoma (RCC) is the most common primary tumour of the kidney. RCC is a clinically and pathologically heterogenous entity, which has traditionally been classified under two broad categories: clear-cell and non-clear cell.
Robert Wightman   +4 more
core   +1 more source

Home - About - Disclaimer - Privacy